CARMA™ Cellular Therapies

Overview

MaxCyte has developed CARMA™, a novel and proprietary technology for the development of non-viral, human messenger RNA (mRNA)-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies. CARMA [derived from CAR mRNA] utilizes MaxCyte’s Flow Electroporation® technology for highly efficient, non-viral, delivery of one or more mRNA(s) into non-activated PBMCs (peripheral blood mononuclear cells) or isolated immune cells such as T- or NK-cells. CARMA offers the potential for a safer cell therapy, as a result of transient expression of receptor(s) and a non-viral delivery approach. Together, CARMA and the EXPERT™ family of instruments also offer the potential for a significantly streamlined, scalable, and cost-effective GMP manufacturing process without the complexity of virus-based products.

OUR PIPELINE

Our CARMA knowledge and experience, coupled with our strong and growing non-clinical and translational research program and established GMP cell processing capabilities forms the basis of our cell therapy R&D platform and underscores the potential for generating a pipeline of highly differentiated, CARMA cell therapies for cancer as well as other diseases with serious unmet needs.

 
To date, supported by preclinical efficacy, our lead CARMA program, MCY-M11, a mesothelin directed CAR-PBMC therapy, is being evaluated in a Phase I clinical trial for ovarian cancer and peritoneal mesothelioma [NCT03608618]. In addition, we are also advancing research and development of next-generation CARMA-based cell therapies — those potentially engineered with functionality uniquely amenable to the CARMA approach — directed to mesothelin and other novel, undisclosed targets.

 

 

CARMA™ IN THE NEWS

MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update
December 19, 2019
Read Full Release »

MaxCyte to Present at BIO-Europe 2019
November 7, 2019
Read Full Release »

MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients
October 24, 2019
Read Full Release »

MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum
October 15, 2019
Read Full Release »

MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings
September 30, 2019
Read Full Release »

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform
July 23, 2019
Read Full Release »

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
May 8, 2019
Read Full Release »

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
May 1, 2019
Read Full Release »

MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe
March 18, 2019
Read Full Release »

MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019
December 19, 2018
Read Full Release »

MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®
October 30, 2018
Read Full Release »

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors
October 10, 2018
Read Full Release »

MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences
August 29, 2018
Read Full Release »

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
16 July 2018
Read Full Release »

MaxCyte, Inc. to Present at 2018 BIO International Convention
May 29, 2018
Read Full Release »

MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer
April 25, 2018
Read Full Release »

MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month
March 12, 2018
Read Full Release »

MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
March 2, 2017
Read Full Release »

MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
December 21, 2016
Read Full Release »

MaxCyte Appoints Executive Vice President, Business and Strategic Development
November 2, 2016
Read Full Release »

MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
April 21, 2015
Read Full Release »

CARMA Scientific Publications

2017 AACR Annual Meeting Abstract: Development of anti-human mesothelin chimeric antigen receptor (CAR) messenger RNA (mRNA) transfected peripheral blood mononuclear cells (CARMA) for the treatment of mesothelin-expressing cancers

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo